{
  "id": "d105c211b2467ef8",
  "title": "STAT+: On Day 1 of JPM, no blockbuster headlines, but biotech newsmakers still move markets",
  "description": "So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs \u2014 the most ever for the pre-JPM timespan.",
  "content": "So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs \u2014 the most ever for the pre-JPM timespan.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/01/12/jpm-2026-day-1-top-stories-bridgebio-moderna-eli-lilly-readout-newsletter/?utm_campaign=rss",
  "published_at": "2026-01-12T20:52:28+00:00",
  "fetched_at": "2026-01-13T00:20:01.657666+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": null,
  "raw_data": {
    "title": "STAT+: On Day 1 of JPM, no blockbuster headlines, but biotech newsmakers still move markets",
    "description": "So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs \u2014 the most ever for the pre-JPM timespan.",
    "url": "https://www.statnews.com/2026/01/12/jpm-2026-day-1-top-stories-bridgebio-moderna-eli-lilly-readout-newsletter/?utm_campaign=rss",
    "published": "2026-01-12T20:52:28+00:00",
    "source": "STAT"
  }
}